The company

The Organization

Scientific Founders

Thomas P. Stossel, MD (Founding Scientist, Director)

American Cancer Society Professor of Medicine, Harvard Medical School
Co-Director, Hematology Division, Brigham & Women’s Hospital
Renowned Harvard clinician/researcher (mechanisms that enable cells to crawl & metastasize)
AB, Princeton University; MD Harvard Medical School

Po-Shun Lee, MD (Founding Scientist)

Instructor in Medicine at Harvard Medical School
Attending, Pulmonary & Critical Care Division, Brigham & Women’s Hospital
Gelsolin assay studies & pre-clinical studies of gelsolin in various animal models

Executive Team

James W. Fordyce (Chairman)

Managing Partner, MEDNA Partners (private advisory firm)
Chairman of the Board of the Albert & Mary Lasker Foundation
Founding General Partner, Prince Ventures
MBA, Harvard Bus. School; degrees from Oxford University and University of Pennsylvania

Ashleigh W. Palmer (Chief Executive Officer, Director)

CEO, INOtherapeutics (INOmax®, ICU drug and first selective pulmonary vasodilator)
Chairman and turn-around CEO of Restoragen (recombinant peptide company)
Founder of Creative BioVentures Corporation (life sciences strategic advisory firm)
Interim/turn-around CEO, CanFite BioPharma, IPO (TASE) 09/05, 600% oversubscribed
VP of Business Development for BOC Group’s Ohmeda Pharmaceuticals
MBA, University of Bradford; BSc (hons) Biochem. and Molecular Biology, Manchester University

Richard C. Straube, MD, MSc (Chief Medical Officer)

CMO, INOtherapeutics (INOmax®, ICU drug and first selective pulmonary vasodilator)
Director, Medical Affairs, T-Cell Sciences, Inc.
Senior Director, Infectious Diseases and Immunology & Clinical Research, Centocor, Inc.
MD (University of Chicago); MSc in epidemiology (London School of Hygiene & Tropical Medicine

Executive Team supported by world-class advisers and consultants in key fields

Randy Rupp, PhD – Manufacturing and Process Sciences
Bill Kerns, DVM, MS – Preclinical Development and Drug Safety

Board of Directors

James W. Fordyce (Chairman)
Scott Coleridge
Gerald Chan
Thomas P. Stossel, MD

Investor

The largest investor in CBC is the Morningside Group (www.morningside.com). This group is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside Group was one of the earliest institutional investors in China's internet industry and in recent years has been an active investor in China's emerging biotechnology sector.

The Company’s History

Critical Biologics Corporation, based in Cambridge, MA, began fund raising in 2006 with the strategic intent to develop and commercialize diagnostics and therapeutics that predict and regulate inflammatory responses to life-threatening diseases. In particular, CBC is focused on a theranostic approach to treat critical care patients with low plasma gelsolin levels at high risk of life-threatening complications. Gelsolin was first discovered by Dr. Tom Stossel, American Cancer Society Professor of Medicine at Harvard Medical School and Director of the Translational Medicine Division and Senior Physician in the Hematology Division at Brigham & Women’s Hospital. In October 2006, CBC entered into an agreement with Brigham & Women’s Hospital to license technology and intellectual property pertaining to the therapeutic and diagnostic use of plasma gelsolin to predict and pre-emptively treat a variety of medically and economically important conditions.

Strategic Partners

CBC has partnered with QSV Biologics, Ltd. (www.qsvbiologics.com) for the manufacturing of pharmaceutical rhu-pGelsolin. QSV is an international cGMP biologics contract manufacturer (CMO) providing microbial fermentation & cell culture, and purification services. QSV’s facility has a 10 yr track-record including an Establishment License for manufacturing clinical trial and commercial biologics. QSV was the sole recipient of the prestigious international Frost & Sullivan “Customer Value Enhancement Award” in 2005. QSV’s clientele span three continents and develop protein therapeutics, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value.